We are live on ! Find out more
PYXS icon

Pyxis Oncology
PYXS

38 hedge funds and large institutions have $36.6M invested in Pyxis Oncology in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 8 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 8

1.83% less ownership

Funds ownership: 61.04% → 59.21% (-1.8%)

3% less funds holding

Funds holding: 39 → 38 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

23% less capital invested

Capital invested by funds: $47.7M → $36.6M (-$11.1M)

Holders
38
Holders Change
-1
Holders Change %
-2.56%
% of All Funds
0.65%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
13
Reduced
8
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
O
OrbiMed
New York
+$2.22M
2
Geode Capital Management
Geode Capital Management
Massachusetts
+$206K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$178K
4
Renaissance Technologies
Renaissance Technologies
New York
+$140K
5
BCM
Bridgeway Capital Management
Texas
+$131K

Top Sellers

1
CS
Credit Suisse
Switzerland
-$2.13M
2
RI
RTW Investments
New York
-$1.62M
3
RCM
RA Capital Management
Massachusetts
-$493K
4
Millennium Management
Millennium Management
New York
-$138K
5
E
Ergoteles
New York
-$87K
Name Holding Trade Value Shares
Change 		Change in
Stake
LCM
1
Laurion Capital Management
New York
$6.25M – – –
BI
2
BVF Inc
California
$5.79M – – –
Citadel Advisors
3
Citadel Advisors
Florida
$3.02M +$25.7K +9,849 +0.6%
PA
4
Perceptive Advisors
New York
$3.01M – – –
TCM
5
Tang Capital Management
California
$2.78M +$84.9K +32,489 +2%
Barclays
6
Barclays
United Kingdom
$1.87M – – –
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.81M +$178K +68,304 +8%
NM
8
Newtyn Management
New York
$1.58M – – –
RCM
9
RA Capital Management
Massachusetts
$1.51M -$493K -188,740 -20%
HA
10
HHLR Advisors
Cayman Islands
$1.51M – – –
TCM
11
Tekla Capital Management
Massachusetts
$1.4M – – –
CAM
12
Cormorant Asset Management
Massachusetts
$1.32M +$3 +1 +0%
ACP
13
Acuta Capital Partners
California
$1.32M +$62.7K +24,009 +4%
Citigroup
14
Citigroup
New York
$615K -$269 -103 -0%
LGM
15
Logos Global Management
California
$434K – – –
BlackRock
16
BlackRock
New York
$406K +$3.27K +1,250 +0.6%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$371K +$206K +78,974 +72%
CS
18
Credit Suisse
Switzerland
$299K -$2.13M -813,447 -84%
Renaissance Technologies
19
Renaissance Technologies
New York
$254K +$140K +53,431 +71%
Morgan Stanley
20
Morgan Stanley
New York
$240K -$38.9K -14,877 -11%
BCM
21
Bridgeway Capital Management
Texas
$237K +$131K +50,000 +71%
Millennium Management
22
Millennium Management
New York
$177K -$138K -52,977 -37%
Two Sigma Investments
23
Two Sigma Investments
New York
$74K -$12.1K -4,619 -11%
State Street
24
State Street
Massachusetts
$61K – – –
Northern Trust
25
Northern Trust
Illinois
$52K +$22.6K +8,656 +49%
1
2

PYXS Hedge Fund Activity: Q3 2022 in Review

38 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Pyxis Oncology (PYXS) for Q3 2022, worth a combined $36.6M — down 23% from $47.7M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of PYXS and 5 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 13 added.

The largest buyer was OrbiMed, opening a new position worth an estimated $2.22M. The largest seller was Credit Suisse, cutting an estimated $2.13M.

  • 38 institutional investors held Pyxis Oncology (PYXS) as of Q3 2022, down from 39 in Q2 2022.
  • Funds reported $36.6M of Pyxis Oncology stock for Q3 2022, down 23% quarter-over-quarter.
  • 5 funds opened new Pyxis Oncology positions in Q3 2022 and 6 closed out, a net change of -1 holder.
  • The largest Pyxis Oncology buyer in Q3 2022 was OrbiMed, an estimated $2.22M added.
  • The largest Pyxis Oncology seller in Q3 2022 was Credit Suisse, an estimated $2.13M sold.

Based on aggregated 13F filings for Q3 2022.